EVGN Earnings Prediction
The chart below shows how EVGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EVGN sees a +8.02% change in stock price 10 days leading up to the earnings, and a -6.49% change 10 days following the report. On the earnings day itself, the stock moves by -4.85%. This data can give you a slight idea of what to expect for the next quarter's release.
EVGN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.80M
-52.32%
96.50%
Gross Margin
39.81%
-53.94%
-3.49%
Operating Margin
-415.09%
273.82%
-37.77%
Net Margin
-457.63%
346.82%
-30.11%
EPS
-1.31
-1537.50%
-87.64%
No Data Available
EVGN Earnings Analysis
EVOGENE LTD. Corporation (EVGN.O) Earnings Conference Call
Positive
Revenue Growth Comparison: In the first nine months of 2024, total revenues reached approximately $6.9 million compared to approximately $5.1 million in the first nine months of 2023, indicating a significant growth in revenue.
Revenue Decline Analysis: In Q3 2024, total revenues reached approximately $1.8 million compared to approximately $3.8 million in Q3 2023, primarily based on the Casterra's seeds sales.
Projected Revenue Growth: For the full year 2024, Evogene anticipates continued revenue growth compared to the previous year, mainly due to Casterra's supply of existing seed orders.
Strong Cash Position: Evogene held consolidated cash, cash equivalents, and short-term bank deposits of approximately $20 million as of September 30, 2024, indicating a strong cash position.
Net Financial Expenses Management: In Q3 2024, the company recorded net financial expenses related to warrants of approximately $892,000, reflecting effective cost management strategies.
Negative
Revenue Decline Analysis: In Q3 2024, total revenues reached approximately $1.8 million compared to approximately $3.8 million in Q3 2023, indicating a significant decline in revenue.
Operating Loss Decrease: Operating loss for the first nine months of 2024 was approximately $17.6 million, which is a decrease from approximately $18.9 million in the same period of the previous year, reflecting ongoing financial challenges.
Projected Cash Usage Decline: The projected cash usage for 2024 is expected to be around $8 million to $10 million, marking a notable 20% to 36% decrease from approximately $12.5 million in 2023.
G&A Expense Increase: G&A expenses in Q3 2024 included expenses of approximately $1.4 million resulting from Evogene's fundraising and allowance for doubtful debt, indicating increased financial strain.
Increased Net Loss: The net loss for the third quarter of 2024 was approximately $8.2 million compared to approximately $3.9 million in the same period of the previous year, highlighting worsening financial performance.
EVGN FAQs
How does EVGN typically perform around its earnings report dates?
Is Evogene Ltd. (EVGN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
EVGN Earning Call Sentiment
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
EVGN.O
7.96%Positive
The earnings call highlighted mixed results: a significant revenue increase for the first nine months of 2024 and reduced operating losses, but a sharp revenue drop in Q3 2024 and increased net loss. The Q&A revealed uncertainties around Casterra's orders and lack of clarity on future revenues, which dampens optimism. The company's strategic partnerships and reduced cash usage are positive, but the increased G&A expenses and lack of guidance on insider ownership are concerns. Overall, the sentiment balances out to a neutral outlook.